Rifampicin efficacy against doxorubicin-induced cardiotoxicity in mice

The Egyptian Heart Journal

Table 1 Experimental design, timeline for drug administration, and end of experiment in different groups

Group name	Description	Drug treatment	Dose (mg/kg/day)	Refs.	Frequency	Exp. days of injection	Route	Exp. duration	Day of scarification
Control	Negative control	–	–	–	–	–	–	14 days	14
Doxorubicin	Positive control (cardiotoxicity)	Doxorubicin	5	[16, 17]	3 times (4 day intervals)	1,5,9	i.p	14 days	14
Doxorubicin + Rifampicin 0.107	First treated group with rifampicin	Doxorubicin	5	[16, 17]	3 times (4 day intervals)	1,5,9	i.p	14 days	14
Doxorubicin + Rifampicin 0.107	First treated group with rifampicin	Rifampicin	0.107	[11]	Once daily	1–14	i.p	14 days	14
Doxorubicin + Rifampicin 0.214	Second treated group with rifampicin	Doxorubicin	5	[16, 17]	3 times (4 day intervals)	1,5,9	i.p	14 days	14
Doxorubicin + Rifampicin 0.214	Second treated group with rifampicin	Rifampicin	0.214	–	Once daily	1–14	i.p	14 days	14

Doxorubicin stock solution (2 mg/mL) was diluted in saline (10%, v/v) before injection whereas rifampicin was prepared as a stock solution of 1 mM concentration in absolute ethanol and it was diluted also in saline (10%, v/v) before injection
i.p. Intraperitoneal, Ref. Reference, n 10 mice in each group